Characterising Patient Pathways to the Diagnosis of Idiopathic Pulmonary Fibrosis: Real World Data Study

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/30193
• EU PAS number:
  EUPAS20994
• Study ID:
  30193
• Official title and acronym:
  Characterising Patient Pathways to the Diagnosis of Idiopathic Pulmonary Fibrosis: Real World Data Study
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  An exploratory historical UK database study characterising patient pathways to diagnosis of IPF, identifying and quantifying blocks and red flags through primary, secondary, and tertiary care settings.
• Study status:
  Finalised

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 28/06/2017

Actual: 28/06/2017

Study start date

Planned: 01/06/2018

Actual: 07/07/2018

Date of final study report

Planned: 31/08/2018

Actual: 28/08/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Roche

Study protocol

Initial protocol

OPRI-R1704_Protocol_Characterising patient pathways to IPF diagnosis_Protocol_V2.1

Updated protocol

OPRI-R1704_Protocol_Characterising patient pathways to IPF diagnosis_Protocol_V2.3 clean

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable